In Tuesday’s Wall Street session, Akebia Therapeutics Inc (NASDAQ:AKBA) shares traded at $3.42, up 5.23% from the previous session.
AKBA stock price is now 47.59% away from the 50-day moving average and 78.43% away from the 200-day moving average. The market capitalization of the company currently stands at $898.22M.
With the price target of $7, Leerink Partners recently initiated with Outperform rating for Akebia Therapeutics Inc (NASDAQ: AKBA). On April 01, 2025, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $6, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Butler John P., CEO and President sold 46,409 shares of the company’s stock on Mar 03 ’25. The stock was sold for $84,928 at an average price of $1.83. Upon completion of the transaction, the CEO and President now directly owns 2,557,921 shares in the company, valued at $8.75 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, SVP, Chief Medical Officer Burke Steven Keith sold 7,144 shares of the business’s stock. A total of $13,074 was realized by selling the stock at an average price of $1.83. This leaves the insider owning 809,090 shares of the company worth $2.77 million. A total of 4.10% of the company’s stock is owned by insiders.
During the past 12 months, Akebia Therapeutics Inc has had a low of $0.80 and a high of $3.26. As of last week, the company has a debt-to-equity ratio of 8.39, a current ratio of 2.23, and a quick ratio of 2.02.
The company reported revenue of $57.34 million for the quarter, compared to $32.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 75.84 percent.
